AdobeStock_1365861209

Insulin Pricing Litigation for Public Entities

Frantz Law Group represents public entities harmed by unlawful pricing practices carried out by insulin manufacturers and pharmacy benefit managers.

The Best Of The Best

Recognized by Top
Organizations Nationwide

2021-Best-Law-Firms-Standard-Badge-2048×2019
Best-Law-Firms-Standard-Badge-20221
badge-2017
acc_10
Top-10-Trucking-Trial-Lawyers
MTTLA-Top-251

We Support Public Entities Impacted by Inflated Insulin Costs

More than 34 million Americans rely on insulin. Our team helps public agencies recover funds lost to illegal pricing practices.

Diabetes Nationwide

Over 34.2 million Americans have diabetes, and another 88 million have prediabetes.

Essential Daily Use

More than 7 million people require insulin every day to manage their health.

Extreme Price Inflation

Certain insulin prices increased over 1000 percent since 2003.

Minimal Innovation

Manufacturers invested small portions of profits into R&D despite major price hikes.

Market Control

Three manufacturers control 99 percent of insulin sales by value.

PBM Influence

Three PBMs control 89 percent of the national PBM market and drive rebate structures.

How the Insulin Pricing Scheme Works

Manufacturers and PBMs engage in coordinated practices that inflate insulin costs for public plans and taxpayers.

Hidden Rebate Demands

PBMs demand undisclosed rebates, raising costs.

Locked Step Price Increases

Manufacturers raise insulin prices together to keep PBM access and boost profits.

Reduced Production Costs

Efficiency improvements lowered costs, yet list prices continue to surge.

Rising Costs to Public Plans

In 2016, the average diabetic spent $5,705 per year on insulin.

Limited Innovation

Insulin unchanged since 1990s; prices keep rising.

Success

WHY CHOOSE FRANTZ LAW GROUP

Frantz Law Group has extensive experience representing counties, cities, townships, and school districts in complex, large-scale litigation against major corporations.
  • Experienced Public Entity Representation
    We have represented public agencies nationwide in significant litigation involving financial harm and corporate misconduct.
  • Deep Knowledge of the Insulin Supply Chain-Our team understands how manufacturers and PBMs collaborate to raise prices through secret rebates and formulary manipulation.
  • Proven Record in Complex Litigation
    Our firm has secured major recoveries for public entities in cases involving widespread corporate wrongdoing.
  • Pursuing Maximum Remedies
    We seek compensation for wrongfully paid costs, treble damages where applicable, disgorgement, punitive damages, and injunctive relief.
250825_BL_FLG-0255F v03
AdobeStock_511678178

Start Your Injury
Claim Today

If your public entity has overpaid for insulin due to unlawful pricing practices, you may be entitled to significant recovery.

Frequently Asked
Questions

Here’s what clients ask us most before filing a
claim.

Counties, cities, townships, school districts, and other public entities that fund health plans for employees, dependents, and retirees.

Manufacturers and PBMs participate in coordinated pricing, including secret rebates and lockstep price increases that inflate costs.

Manufacturers Eli Lilly, Novo Nordisk, and Sanofi, and PBMs Express Scripts, CVS Caremark, and OptumRx.

Recovery of wrongfully paid funds, treble damages where allowed, injunctive relief, punitive damages, and disgorgement.

PBMs demand large, undisclosed rebates for formulary placement, pushing manufacturers to raise prices.

Studies showing insulin could cost $48 to $71 per year or under $2 per vial, despite real-world costs exceeding $5,705 annually for many diabetics.